BOSTON ( TheStreet) -- Adam Feuerstein's take on the biotech week that ended Nov. 12, 2010:

The week's best-performing stocks in the sector: Aastrom Biosciences ( ASTM) (+48%), AspenBio Pharma ( APPY) (+32%), Bionovo ( BNVO) (28%), Vermillion ( VRML) (+26%) and Genomic Health ( GHDX) (+20%).

Is it any coincidence that Aastrom filed a $75 million mixed shelf registration Friday?

Human Genome Sciences ( HGSI): FDA Reviews Lupus Drug

The week's worst-performing stocks: Surmodics ( SRDX) (-30%), Epicept ( EPCT) (-28%), Metabolix ( MBLX) (-25%), Angiotech Pharmaceuticals ( ANPI) (-21%) and Repros Therapeutics ( RPRXD) (-19%).

Cadence Pharmaceuticals ( CADX) sold 11.5 million shares at $8, raising $86 million to fund commercial launch of Ofirmev, a hospital-based intravenous form of acetameniphan.

> > Bull or Bear? Vote in Our Poll

Athersys ( ATHX) received FDA clearance to start phase II study of Multistem stem cell therapy for inflammatory bowel disease.

Arena Pharma ( ARNA): 'Marginal' Obesity Drug Now Unsafe?

Research abstracts for American Society of Hematology annual meeting were posted online.

Cerus ( CERS) priced 7.37 million stock units (stock and warrants) at $2.85 a unit, raising $20 million.

FDA cleared Polymedix ( PYMX.OB) to begin human clinical trials of antibiotic PMX-30063.

Osiris Therapeutics ( OSIR) Drags Feet on U.S. Approval Filing

Dendreon ( DNDN) filed for FDA approval of an expansion to its Provenge manufacturing plant in New Jersey, while the Centers for Medicare and Medicaid (CMS) released the technical assessment of Dendreon's Provenge ahead of next week's National Coverage Determination meeting.

Micromet ( MITI) sold 9.9 million shares at $7.30, raising $72 million.

This week's Biotech Stock Mailbag: Theratechnologies ( TH.TO), Arena Pharmaceuticals, Amarin ( AMRN), and Osiris Therapeutics.

A preview of next week's important regulatory meetings facing Human Genome Sciences, Dendreon and MELA Sciences ( MELA).

Human Genome: Benlysta FDA Panel Preview

Glaxo ( GSK) Lawyer Indicted for Obstructing the FDA (via Pharmalot)

European Drug Approval Agency Looking for new leader (via invivo blog)

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:
Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.